Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies
复制标题
DOI：
10.1681/asn.2014010093
复制
发表时间：
2015-09-01
影响因子：
13.6
通讯作者：
de Boer, Rudolf A.
中科院分区：
文献类型：
--
作者：
Drechsler, Christiane;Delgado, Graciela;de Boer, Rudolf A.
Galectin-3与肾脏疾病、实验性肾纤维化和肾病有关。然而，Galectin-3、肾功能和不良结局之间的联系还没有被描述。我们在两个大的患者队列中研究了这种关联，涉及广泛的肾功能。我们测量了德国糖尿病透析(4D)研究(1168名2型糖尿病透析患者)和路德维希港风险与心血管健康(LURIC)研究(2579名有冠状动脉造影的患者)基线样本中Galectin-3的浓度。患者分为三组：EGFR=90ml/min/1.73m~2，60-ml/min/1.73m~2(2)；
Galectin-3 has been linked to incident renal disease, experimental renal fibrosis, and nephropathy. However, the association among galectin-3, renal function, and adverse outcomes has not been described. We studied this association in two large cohorts of patients over a broad range of renal function. We measured galectin-3 concentrations in baseline samples from the German Diabetes mellitus Dialysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2579 patients with coronary angiograms). Patients were stratified into three groups: eGFR of >= 90 ml/min per 1.73 m2, 60-89 ml/min per 1.73 m(2), and